98%
921
2 minutes
20
Introduction: Use of implantable loop recorder (ILR) for the diagnosis and documentation of cardiac arrhythmia has gained popularity during the last decade. Most ILRs are accompanied by remote monitoring (RM) devices, which allow automated daily interrogations of the ILR. These transmit arrhythmic or pause alerts to the treating clinic, enabling timely medical attention and treatment. Although ILR RM transmissions have been shown to have significant false positive alerts, a true positive alert suggesting a wrong arrhythmia diagnosis has not been shown to date.
Methods And Results: We revised all ILR pause transmissions arriving to our hospital device clinic during 2024, looking for pause alerts which were initially misdiagnosed. We report a case series of patients in whom a RM pause alert has been transmitted with a suspected apparent diagnosis of sinus arrest. However, when interrogating the ILR in clinic, these episodes were diagnosed as high-degree atrioventricular block (AVB) pauses, for which an urgent permanent pacemaker (PPM) might be indicated. Review of these cases revealed that in contrast with the automated RM PDF alerts, in which the figure resolution cannot be changed (and thus small P waves may be unnoticed), the raw-data episode recording on the RM web page enables one to increase the image resolution to clearly discern initially unnoticed non-conducted P waves.
Conclusion: ILR RM pause alerts should always be reviewed via the raw-data RM web page or alternatively via ILR device interrogations, to achieve a sufficiently high-resolution image to assure these pauses are not due to AVB.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075912 | PMC |
http://dx.doi.org/10.1111/jce.16634 | DOI Listing |
Heart
August 2025
Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Campania, Italy
Background: False-positive (FP) alerts from implantable loop recorders increase clinical workload and may delay appropriate intervention. AccuRhythm AI, a cloud-based filtering algorithm, is designed to reduce these alerts in Reveal LINQ and LINQ II devices. This study assessed the algorithm's effect on FP and clinician burden reduction, with a focus on the influence of R-wave sensing amplitude.
View Article and Find Full Text PDFEuro Surveill
August 2025
Centers for Disease Control and Prevention, Fort Collins, Colorado, United States.
A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
May 2025
Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel.
Introduction: Use of implantable loop recorder (ILR) for the diagnosis and documentation of cardiac arrhythmia has gained popularity during the last decade. Most ILRs are accompanied by remote monitoring (RM) devices, which allow automated daily interrogations of the ILR. These transmit arrhythmic or pause alerts to the treating clinic, enabling timely medical attention and treatment.
View Article and Find Full Text PDFJ Particip Med
February 2025
Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, United Kingdom.
Background: Diabetic foot ulcers are common and costly. Most cases are preventable, although few interventions exist to reliably support patients in performing self-care. Emerging technologies are showing promise in this domain, although patient and health care provider perspectives are rarely incorporated into digital intervention designs.
View Article and Find Full Text PDFJ Clin Anesth
December 2024
Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States of America.
Study Objective: To decrease the occurrence of remifentanil waste of 1 mg or more (1 full vial) by 25 % in our surgical division while maintaining satisfaction of 60 % of providers by using a remifentanil mixing workflow.
Design: A time series-design quality improvement initiative targeted preventable remifentanil waste. A period of active interventions, followed by a pause and reinstatement of a system intervention, was used to validate its effectiveness.